JP2021506898A - ニコチンアミドリボシドクロリドの結晶形態 - Google Patents

ニコチンアミドリボシドクロリドの結晶形態 Download PDF

Info

Publication number
JP2021506898A
JP2021506898A JP2020534265A JP2020534265A JP2021506898A JP 2021506898 A JP2021506898 A JP 2021506898A JP 2020534265 A JP2020534265 A JP 2020534265A JP 2020534265 A JP2020534265 A JP 2020534265A JP 2021506898 A JP2021506898 A JP 2021506898A
Authority
JP
Japan
Prior art keywords
subject
crystalline form
sleep
administering
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020534265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506898A5 (https=
Inventor
マルコトゥッリ，エリック
アルミナナ，ダン
デリンガー，ライアン
モリス，マーク
Original Assignee
エリシウム ヘルス，インコーポレーテッド
エリシウム ヘルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エリシウム ヘルス，インコーポレーテッド, エリシウム ヘルス，インコーポレーテッド filed Critical エリシウム ヘルス，インコーポレーテッド
Publication of JP2021506898A publication Critical patent/JP2021506898A/ja
Publication of JP2021506898A5 publication Critical patent/JP2021506898A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2020534265A 2017-12-22 2018-12-20 ニコチンアミドリボシドクロリドの結晶形態 Pending JP2021506898A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609512P 2017-12-22 2017-12-22
US62/609,512 2017-12-22
PCT/US2018/066769 WO2019126482A1 (en) 2017-12-22 2018-12-20 Crystalline forms of nicotinamide riboside chloride

Publications (2)

Publication Number Publication Date
JP2021506898A true JP2021506898A (ja) 2021-02-22
JP2021506898A5 JP2021506898A5 (https=) 2021-11-18

Family

ID=66993830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534265A Pending JP2021506898A (ja) 2017-12-22 2018-12-20 ニコチンアミドリボシドクロリドの結晶形態

Country Status (6)

Country Link
US (2) US11414407B2 (https=)
EP (1) EP3727400A4 (https=)
JP (1) JP2021506898A (https=)
CN (1) CN112020363A (https=)
CA (1) CA3086535A1 (https=)
WO (1) WO2019126482A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180303861A1 (en) 2017-04-24 2018-10-25 Eric Marcotulli Treating and preventing kidney damage
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
EP3999518A2 (en) 2019-07-19 2022-05-25 Biosynth AG Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
WO2024259359A2 (en) 2023-06-14 2024-12-19 ChromaDex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014927A2 (en) * 2014-07-24 2016-01-28 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016144660A1 (en) * 2015-03-09 2016-09-15 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
JP2017518306A (ja) * 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
WO2017218580A1 (en) * 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
CN1262556C (zh) 1997-02-06 2006-07-05 印斯拜尔药品股份有限公司 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
JP3748536B2 (ja) 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
JP4058106B2 (ja) 2005-02-18 2008-03-05 アストラゼネカ アクチボラグ 抗菌性のピペリジン誘導体
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
AU2006339607A1 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US20100047177A1 (en) 2007-01-26 2010-02-25 Washington University Methods and compositions for treating neuropathies
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2010002586A2 (en) 2008-06-30 2010-01-07 Elc Management Llc Topical compositions comprising isonicotinamide
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
US20120164670A1 (en) 2009-06-23 2012-06-28 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity
EP2456772A4 (en) 2009-07-24 2013-02-27 Amazentis Sa COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
US9603862B2 (en) 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
US20130165398A1 (en) 2010-03-29 2013-06-27 Paul Hochegger Concentration-enhancing drink
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
CA2840516A1 (en) 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
CN110051672A (zh) 2012-07-09 2019-07-26 诺格罗有限责任公司 使用膳食补充剂预防酒精反应
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
KR101914844B1 (ko) 2013-10-24 2018-11-02 더 프록터 앤드 갬블 캄파니 피부 미백 화장 조성물 및 방법
KR20150050406A (ko) 2013-10-29 2015-05-08 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
CA2928656C (en) 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
MX373132B (es) 2013-11-12 2020-05-25 Ortho Nutra Llc Suplemento a base de teacrina y método de uso del mismo.
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
CN107073027A (zh) 2014-07-17 2017-08-18 斯克利普斯研究院 增强癌症疗法的方法和组合物
CN115176998A (zh) * 2016-04-14 2022-10-14 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
EP3999518A2 (en) 2019-07-19 2022-05-25 Biosynth AG Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CN111808156A (zh) 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518306A (ja) * 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
WO2016014927A2 (en) * 2014-07-24 2016-01-28 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US20170210774A1 (en) * 2014-07-24 2017-07-27 W. R. Grace & Co.-Conn. Crystalline Form Of Nicotinamide Riboside
WO2016144660A1 (en) * 2015-03-09 2016-09-15 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2017218580A1 (en) * 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRAYAMA, N., 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 2008, pages 57 - 84, ISSN: 0005027909 *

Also Published As

Publication number Publication date
EP3727400A1 (en) 2020-10-28
US20210094936A1 (en) 2021-04-01
US11414407B2 (en) 2022-08-16
EP3727400A4 (en) 2021-10-20
US20230063175A1 (en) 2023-03-02
CA3086535A1 (en) 2019-06-27
US12043616B2 (en) 2024-07-23
CN112020363A (zh) 2020-12-01
WO2019126482A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
JP2021506898A (ja) ニコチンアミドリボシドクロリドの結晶形態
US11629163B2 (en) Methods of synthesizing nicotinamide riboside
KR101691536B1 (ko) 신규 fak 저해제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물
JP2021105030A (ja) ニコチンアミドリボシドの結晶形
RU2121998C1 (ru) Производные пиримидина, способ их получения, фармкомпозиция
RU2268732C2 (ru) Способы лечения митохондриальных нарушений
RU2625309C2 (ru) Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
US20210290578A1 (en) Mixture of fatty acids for use in the treatment of inflammatory pathologies
JP6122862B2 (ja) １−（５，６−ジクロロ−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−１ｈ−ピラゾール−４−カルボン酸のメグルミン塩製剤
KR20180073582A (ko) β-니코틴아미드 모노뉴클레오티드의 결정 형태
CZ302269B6 (cs) Farmaceutický prostredek pro lécbu artropatií
JP6289659B2 (ja) 五環トリテルペン構造修飾化合物とその調製方法及び応用
EA020198B1 (ru) N-ацетил-(r)-(-)-3-(4-аминофенил)-2-метоксипропионовая кислота, содержащая ее фармацевтическая композиция, способ лечения
JP7201688B2 (ja) 置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP7294734B2 (ja) カリウムチャネル調節剤としての化合物ならびにその調製および応用
TW202317518A (zh) 作為鉀通道調節劑的化合物及其製備和應用
JP2012530492A (ja) 真皮細胞の発毛促進能を増大させるための方法および組成物
CN115944626A (zh) 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
FR3110836A1 (fr) Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
CN108368117B (zh) 一种取代的咪唑并喹唑啉化合物及其药物组合物
DE60202345T2 (de) 5-heteroatomsubstituierte Pyrazole
DE60202184T2 (de) 5-(Alkyliden-cycloalkyl)- und 5-(Alkyliden-heterocyclyl)-Pyrazole
EP2538941A1 (en) Pyrrolidine substituted flavones for the treatment of inflammatory disorders
KR102599625B1 (ko) 셀레늄 화합물을 유효성분으로 포함하는 항암제 스트레스를 받은 세포 제거용 조성물
JPH11505240A (ja) 減量用薬剤

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230404